When Will Generic Wegovy Be Available?

Apotex, a Canadian drugmaker, sells a weight-loss injection called Sevmia, and Health Canada says it “is a generic version of Wegovy.” Health Canada authorized it on June 29, 2026, as the country’s first generic semaglutide injection for weight loss. In India, generic semaglutide went on sale on March 21, 2026, the day after the core patent expired. Sun Pharmaceutical, Zydus Lifesciences and Alkem Laboratories already had Indian approval, since January, to sell generic versions of Wegovy and Ozempic. In China, Jiuyuan Genetic Biopharmaceutical has a generic Wegovy called Jikeqin under review by the regulator, which accepted the application in February 2026.

So the answer to when will generic wegovy be available is: already, in several countries, and not for years in the United States. The US compound patent on semaglutide has been extended to December 5, 2031, and Novo Nordisk, which makes Wegovy, reports 2032 as the effective US compound expiry for Ozempic, Rybelsus and Wegovy. Behind that sits a stack of later patents, several specific to Wegovy and its new higher dose, running as late as 2041. Whether those later patents actually keep generics out is not settled, because patents get challenged and lawsuits get settled. But 2032 is the floor.

Where generic Wegovy is already available

The Canadian story is mostly about a fee. Health Canada approved Dr. Reddy’s Laboratories’ generic semaglutide on April 28, 2026, the first G7 country to do so, because Novo Nordisk did not pay a CAD $250 maintenance fee in 2019 (roughly $180) and the patent lapsed permanently. That story has its own article on this site. Sevmia was the third generic semaglutide Health Canada approved, and the first one aimed at weight loss. Pen device patents in Canada are reported to run to at least 2033, which is a separate fight about the plastic part (it turns out the plastic part is also an invention).

India is the big one. Before March 20, 2026, semaglutide in India came under exactly three brand names, Ozempic, Wegovy and Rybelsus, all from Novo. On day one, according to the Generic Guide, “more than a dozen manufacturers” launched. Dr. Reddy’s had announced in July 2025 that it planned to launch generic Wegovy in 87 countries in 2026. It’s fine. That is a normal number of countries.

How patents keep generic Wegovy out of the US until at least 2032

Here is the chain, one link at a time. A drug company gets paid for a molecule by holding a patent on the molecule. US law lets it stretch that patent to make up for time lost in regulatory review, but only once: one patent term extension per active ingredient product. Wegovy is the same molecule as Ozempic (a fact the two brands’ marketing departments tend to mention quietly), so it cannot get a second extension on the same compound patent.

That means the money from Wegovy (Novo’s obesity sales, driven largely by Wegovy, reached DKK 82.3 billion in 2025, roughly $12 billion) has to be protected some other way. The other way is more patents. I assume the internal meeting goes something like this, and I am making it up: “Okay, the molecule is spoken for. What else does it do?”

It does a lot. There is US Patent 11,478,533, covering Wegovy and expiring May 13, 2040, whose official title is “Semaglutide For Use In Medicine.” Translated literally, this is a patent on using the medicine as medicine. There are two patents titled “Semaglutide in medical therapy” expiring October 10, 2038, and one titled “Semaglutide In Cardiovascular Conditions” expiring April 28, 2037. (My job consists largely of reading patent titles aloud and then rereading them more slowly, so I feel qualified to say these titles are doing a lot of work.)

To be fair, this is how the system is built. The molecule patent is the expensive invention; the later patents are claims on specific uses, formulations and doses, and a generic company can try to work around them or knock them down. In Europe, Teva, Generics [UK] Limited and Galenicum Health challenged Novo’s obesity-treatment semaglutide patent in a European Patent Office case numbered T 1701/22. People fight these. How the US stack holds up is a question for lawyers and judges, and it has not been answered.

What the higher-dose Wegovy HD adds to the timeline

On March 20, 2026, the FDA approved a 7.2 mg dose of Wegovy, branded Wegovy HD, for weight loss and long-term maintenance of weight loss in certain adults. That was also, by the calendar, the day India’s core semaglutide patent expired. I am sure this is a coincidence. FDA approval dates are notoriously hard to schedule.

The higher dose comes with its own patent coverage. US Patent 11,318,191, titled “GLP-1 compositions and uses thereof,” covers Ozempic, Wegovy and Wegovy HD and expires February 17, 2041. A generic of the original 2.4 mg Wegovy might not need to copy the 7.2 mg version at all. But if the market moves to the new dose, the generic of the old dose is a generic of last season.

This is the extended edition move, like a movie studio rereleasing a film with twenty more minutes. A made-up scenario, to be clear: Wegovy HD is followed in 2039 by Wegovy HD Plus at a higher dose, then Wegovy Ultra, then a 50 mg Wegovy Director’s Cut that comes in a commemorative pen, each with a fresh patent expiring fifteen years later, until the last generic company files its application for the 2.4 mg version in 2071 and discovers that the only remaining patients on 2.4 mg are its own employees. That will not happen. I guess the reason it will not happen is that doses are limited by what bodies tolerate, which is a better constraint than most in patent law.

What happens to the price when the generics show up

India is the natural experiment. Before generic entry, Wegovy cost up to ₹16,400 a month (roughly $190). Generic semaglutide launched at ₹1,800 to ₹4,200 a month (roughly $20 to $50). Dr. Reddy’s had hoped to price its version up to 60% below Wegovy. Generic semaglutide took 50% of India’s semaglutide sales by value in April 2026.

And then Novo cut its own prices: Ozempic by 36%, and the Wegovy starting dose by 48% on April 1, 2026, about ten days after the generics arrived. Look, between us, notice what that means. The price Novo charged in India on March 20 was not the lowest price at which Novo was willing to sell Wegovy in India. It was the highest price nobody could undercut.

Is that dumb? Not really. A patent is a license to charge what the market will bear until someone else is allowed in, and then you charge what the new market will bear. The patent did exactly what it was designed to do, and so did its expiry.

Where the chain ends up for American patients

In the US, no generic Wegovy has arrived, and the compound patent says none will before 2032. But prices have moved anyway. Novo and WeightWatchers offered one month of Wegovy at $299, a price also available through other telehealth partners until July 31, 2025. As of October 21, 2026, Novo’s own NovoCare Pharmacy lists self-pay Wegovy starting at $199 a month for the pen and $149 for the pill.

Meanwhile, Novo told the US Department of Commerce, in a letter, that Chinese companies shipped enough semaglutide into the US in just over six months to make 1.5 billion starter doses of Wegovy. That is a separate world, the compounding one, and this site leaves it to others. I suppose the point is only that demand for cheap semaglutide in America did not politely wait for 2032.

So follow the chain to the end. Novo gets paid for a molecule, protects the molecule, can only extend it once, patents the uses and the doses, cuts prices the moment generics land in India, and meanwhile sells discounted brand-name Wegovy to Americans who cannot buy the generic. Nobody designed the result.

The cheapest Wegovy in America is Wegovy.